Læknablaðið - 15.04.1996, Qupperneq 29

LÆKNABLAÐIÐ 1996; 82
285
blocade during and after myocardial infarction: an over-
view of the randomized trials. ProgCardiovasc Dis 1985;
27: 335-71.
8. Report of the Sixty Plus Reinfarction Study Research
Group: a double-blind trial to assess long-term oral anti-
coagulant therapy in elderly patients after myocardial
infarction. Lancet 1980; ii: 989-94.
9. Yusuf S, Sleight P. Held P, McMahon S. Routine med-
ical management of acute myocardial infarction. Les-
sons from overviews of randomized controlled trials.
Circulation 1990; 82/Suppl. II: 119-34.
10. Amouyel P, Arveiler D, Cambou JP, Montaye M, Rui-
davets JB. Bingham A, et al. Myocardial Infarction
Case-Fatality Gradient in three French Regions: the
influence of Acute Coronary Care. Int J Epidemiol 1994;
23: 700-9.
11. Cox DR. Regression models and life tables. J R Stat Soc
(B) 1972: 34: 187-220.
12. Gruppo Italiano per lo Studio della Streptochinase nell
’lnfarto Miocardico (GISSI): effectiveness of intrave-
nous thrombolytic treatment in acute myocardial in-
farction. Lancet 1986; i: 397-401.
13. Guðjónsson H. Baldvinsson E, Oddsson G, Ásgeirsson
E, Kristjánsson H. Harðarson Þ. Results of Attempted
Cardiopulmonary Resuscitation of Patients Dying Sud-
denly outside Hospital in Reykjavík and the Surround-
ing Area 1976-1979. Acta Med Scand 1982; 212: 247-51.
14. Kennedy JW, Ritchie JL, Davis KB, Stadius ML, May-
nard C, Fritz JK. The Western Washington Randomized
Trial of Intracoronary Streptokinase in Acute Myocar-
dial Infarction - A 12-Month Follow-up Report. N Engl J
Med 1985 ; 312: 1073-8.
15. Björnsdóttir US, Thorlacius S, Jónsson Á, Lárusson G.
Kransæðastífla á Landakotsspítala 1981-1985. Lækna-
blaðið 1988; 74: 241-3.
16. ISIS-2 (Second International Study of Infarct Survival)
Collaborative Group. Randomised trial of intravenous
streptokinase, oral aspirin, both or neither among 17187
cases of suspected acute myocardial infarction: ISIS-2.
Lancet 1988; iii: 349-60.
17. The Timi Study Group. Comparison of invasive and
conservative strategies after treatment with intravenous
tissue plasminogen activator in acute myocardial infarc-
tion. N Engl J Med 1989; 320: 618-27.
18. Gruppo Italiano per lo Studio della Streptochinase nell
’lnfarto Miocardico (GISSI-2): a factorial randomised
trial of alteplase versus streptokinase and heparin versus
no heparin among 12490 patients with acute myocardial
infarction. Lancet 1990; 336: 65-71.
19. Cerqueira MD, Maynard C, Ritchie JL, Davies KB,
Kennedy JW. Long-Term Survival in 618 Patients from
the Western Washington Streptokinase in Myocardial
Infarction Trials. J Am Coll Cardiol 1992; 20: 1452-9.
20. Gomez-Marin O, Folsom AR, Kottke TE, Wu SH, Ja-
cobs DR, Gillum RF, et al. Improvement in long-term
survival among patients hospitalized with acute myocar-
dial infarction, 1970 to 1980. N Engl J Med 1987; 316:
1353-9.
21. Greenland P, Reicher-Reiss H, Goldbourt U, Behar S;
and the Israeli SPRINT Investigators. In-Hospital and
1-Year Mortality in 1,524 Women After Myocardial In-
farction. Circulation 1991; 83: 484-91.
22. Goldberg RJ, Gore JM, Alpert JS, Osganian V, De
Groot J, Bade J, et at. Cardiogenic shock after acute
myocardial infarction - Incidence and mortality from a
community-wide perspective, 1975-1988. N Engl J Med
1991; 325: 1117-22.
23. Dellborg M, Eriksson P, Riha M, Swedberg K. Declin-
ing hospital mortality in acute myocardial infarction.
Eur Heart J 1994; 15: 5-9.
24. Bleich SD, Nichols TC, Schumacher RR. Effect of He-
parin on Coronary Arterial Patency after Thrombolysis
with Tissue Plasminogen Activator in Acute Myocardial
Infarction. Am J Cardiol 1990; 66: 1412-7.